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Introduction 
 
Kynurenine pathway (KP), which is presented in varying extents in astrocytes, neurons, micro- and 
oligodendroglia as well as in macrophages, endothelial- and dendritic cells in the CNS, is the major 
route of the catabolism of tryptophan (TRP). The tryptophan can convert to L-kynurenine, which can 
metabolism to neuroprotective kynurenic acid (KYNA). The clinical data shows that KYNA and its 
metabolites play an important role in the pathogenesis of multiple neurological disorders like 
Huntingtin disease, Parkinson disease, epilepsy and ischemic stroke.  KYNA is a nonselective 
excitatory amino acid receptor antagonist (like NMDA receptors), participates in the neurotransmission 
of the glutamate. Since KYNA participates in the endogenous protective mechanism, could be a 
suitable pharmacological development target in neurological diseases.  Furthermore, interactions 
between G coupled protein receptors (GPCR) and KYNA is known. 
 
The role of the opioid system in analgesia is well known. The classic receptors of this system are called: 
mu, kappa and delta (µ, κ and δ). The opioid receptors belong to the GPCR superfamily and mostly 
attach to the Gi/o type G-protein. The high number of the opioid receptors is expressed in the 
gastrointestinal tract, spinal cord and in large quantity in the brain cortex and striatum region. In our 
earlier study we showed that KYNA and its analog, KYNA1 (the cation centrum is in C-2 side chain, 
known as SZR72) cannot bind directly to the opioid receptors, but in chronic treatment induces a 
significant change in the receptor function in mouse cortex and striatum. 
 
On the other hand, we hypothesized that KYNA and KYNA1 might influence the opioid receptors 
function by interaction with NMDA receptor. We also investigated the acute effect of KYNA on the 
opioid receptors with the possible involvement of the NMDA receptor, compared to KYNA1. Rats 
were treated with a single intraperitoneal (i.p.) injection of KYNA, KYNA1 or combined with NMDA 
receptor antagonist (MK-801). Furthermore we measured the plasma and spinal fluid concentration 30 
minutes after i.p. administration. Isolated rat brain tissue was treated in in vitro method with KYNA, 
KYNA1 and MK-801 to exclude the blood brain barrier and the peripheral metabolism of the KYNA 
and KYNA1. The cortex and striatum samples were used for [
35S]GTPγS binding experiments and 
opioid receptor functional G-protein activity evaluation. 
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Aim of the study 
 
Several studies revealed that opioid and NMDA blocker co-administration can induce better 
nociceptive effect even in the lower dose of opiate. Therefore, it must be a relationship between KYNA 
and opioid system activity. Since it is determined that both KYNA and opioid system have 
neuroprotective role in pathopysiological conditions, it would be very important to investigate the 
possible reactions and effect of KYNA on opioid system.  But till now there is no coherent and focused 
study about this relationship. Herein for the first time we characterize the binding properties of KYNA 
and KYNA1 towards all three opioid receptors in competition binding assays with radiolabeled 
receptor specific opioid ligands. 
 
The aims of the study presented in this thesis were the following: 
 
 
 
 To measure the binding affinity of KYNA and KYNA1 towards opioid receptors in 
competition binding assays with opioid receptors specific radioligands performed in Chinese 
hamster ovary cell (CHO) membranes overexpressed with the adequate opioid receptor. 
  Investigation of the opioid receptor G-protein activity, the initial phase of GPCR signalling, 
after in vivo and in vitro KYNA and KYNA1 administration in functional [
35S]GTPγS binding 
assays. 
 Investigation of the opioid receptor G-protein activity after chronic treatment of the mice with 
KYNA and KYNA1 by functional [
35S]GTPγS binding assays. 
  To examine the effect of acute treatment with KYNA and KYNA1 on the opioid receptor G-
protein activity in functional [
35S]GTPγS binding assays carried out in rat’s brain membranes. 
 Try to uncover the mechanism of action of KYNA and KYNA1 on opioid system activity 
through in vivo and in vitro experiments. 
 Investigation of possible interaction between opioid receptors and NMDA receptors. 
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Methods 
 
 
1. Animals 
 
1.1. Chronic treatment 
 
C57/B female mice were used, divided in three groups: control (0,9% saline), KYNA (128 mg/kg/day) 
and KYNA1 (200 mg/kg/day). They were treated intraperitoneally with the KYNA/KYNA1 for 9 days. 
On the 9
th
 day and follow by anesthesia the brain cortex and striatum was removed and stored on – 
80 °C. 
 
1.2. Acute treatment 
 
Male SPRD rats were used for in vivo and in vitro experiment. 
 
 In vivo treatment: 
 
All animals for the in vivo experiments received a single i.p. injection. 7 groups were performed in one 
setting: 1.) control (saline), 2.) KYNA1 (296 mg/kg), 3.) KYNA  (189 mg/kg), 4.) MK-801 (1 mg/kg) + 
KYNA1 (296 mg/kg), 5.) MK-801 (1 mg/kg) + KYNA (189 mg/kg). These groups were decapitated 30 
minutes after treatment. The 6
th
 and 7
th
 groups treated with MK-801 (1mg/kg) were decapitated 15 and 
45 minutes after treatment. 
The other setting was included five groups: 1.) control (saline), 2.) KYNA (189 mg/kg), 3.) KYNA1 
(296 mg/kg), 4.) MK-801 (1 mg/kg) + KYNA (189 mg/kg), 5.) MK-801 (1 mg/kg) + KYNA1 (296 
mg/kg). The animals were decapitated 2 hours after treatment. 
 
 In vitro treatment: 
 
The isolated brain after decapitation was placed in isolated organ bath (36 – 37 °C, artificial 
cerebrospinal fluid). For treatment we assigned four groups: control, KYNA, KYNA1 and MK-801. 
KYNA and KYNA1 in 200 μM, MK-801 in 50 μM concentration were added to the bath for 30 
minutes. After treatment the cortex and striatum slices were stored at – 80 °C  till they were using for 
binding assay. 
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2. Functional [35S]GTPγS binding test 
 
During the G-protein binding assay we monitor the exchange of Gαi/o GDP/GTP with a radioactive 
indicator, a non hydrolyzing [
35
S]GTPγS GTP analog. 
The amount of the specific attached [
35
S]GTPγS, binded by the opioid agonist ligands applied in 
increasing concentrations (10
-10
-10
-5
 M) can determine the maximum efficacy of the opioid receptors 
G-protein and ligand potency. 
The examination of the  three opioid receptor was performed with the belonging selectiv ligand: µ 
( DAMGO), κ (dinorfin 1 – 13) and δ (Ile5,6-deltoforin II). 
 
Results 
 Competition binding assay 
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 Chronic treatment 
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 Acute treatment 
 
 
 The blood plasma and CSF concentration levels 
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 In vitro treatment 
 
 
 
 
Discussion and summary of results 
 
In this study we have shown for the first time that KYNA1 and KYNA not only alter opioid receptor 
function after chronic treatment, but also after acute administration in a tissue and receptor specific way. 
Moreover, the effects were modified by MK-801, a selective NMDA receptor antagonist, indicating 
that the changes might be mediated through this receptor. 
The effects seen in vitro experiments in isolated cortex and striatum slices. Our results further support 
previous findings showing the effect of KYNA on the opioid receptors activity. When compared the 
results of chronic (128 and 200 mg/kg/day, i.p., for 9 days) and acute treatments, the data accords just 
in few cases (DOP receptor in cortex and striatum and KOP receptor in striatum by KYNA treatment). 
In the other cases, the effects were opposite (KYNA1 treatment on KOP receptor in the striatum), or it 
did not cause any significant alterations when compared to the appropriate acutely treated group 
(KYNA1 on MOP receptor).  The NMDA receptor has been demonstrated to bind KYNA - although 
with low micromolar affinity also, the interaction of NMDA and opioid receptors have been 
9 
 
demonstrated in many levels. Thus in order to investigate the possible role of the NMDA receptor we 
applied MK-801 (also known as dizocilpine), a highly NMDA receptor selective antagonist. MK-801 
has also been demonstrated to alter opioid receptor-mediated effects,  however it does not bind directly 
to opioid receptors similarly to KYNA. MK-801 alone behaved similarly as KYNA1 or KYNA.     
MK-801 in combination with KYNA1 or KYNA displayed a somewhat less pronunced reduction 
opioid receptor G-protein activity compared to KNYA1 or MK-801 alone.  The results might be 
explained by the impairment of KYNA1/KYNA and MK-801 individual activity when administered 
together, since they exerted similar effects alone, indicating an NMDA receptor mediated effect. The 
same explanation arises in case of MOP and KOP receptors expressed in the striatum, where KYNA 
and MK-801 alone or in combination reduced G-protein signaling.  In case of DOP receptor in the 
cortex, the enhanced agonist (Ile5,6-deltorphin II ) ligand potency followed by 30 minutes KYNA1 
treatment was reduced to control levels by MK-801 pretreatment. Interestingly, MK-801 alone did not 
cause any alterations in ligand potency following 15 or 45 minute administration, which indicates that 
MK-801 inhibited the effect of KYNA1 through NMDA receptor. Furthermore, it also shows that the 
enhanced DOP receptor agonist ligand potency is a KYNA1 specific action, whereas the attenuated 
opioid receptor G-protein activity in the cortex (MOP and DOP receptor) and striatum (all three opioid 
receptors) are also MK-801 related. Since only the 30 minutes duration time showed significant results, 
we carried out HPLC measurements of KYNA1 and KYNA concentration levels in the CSF following 
30 minute treatment. As expected the KYNA CSF concentration levels dramatically reduced compared 
to plasma levels, while in case of KYNA1 there was only a minor difference.  This proves that KYNA1 
passes through the blood-brain barrier more easily than KYNA, which is in agreement with previous 
studies. Additionally, KYNA1 concentrations were significantly lower in plasma compared to KYNA 
indicating that KYNA1 might have been metabolized to KYNA. The observed effect after 30 minutes 
in vivo KYNA1 treatment might be at some part KYNA related. To examine this possibility G-protein 
activity studies were carried out in cortex and striatum slices treated in vitro with KYNA1, KYNA and 
MK-801 in isolated organ baths for 30 minutes. With this setup we can exclude or at least minimize the 
peripheral metabolism and elimination of KYNA1 and also exclude the BBB from the system, yet 
again the possible receptor-receptor interactions can remain intact. Accordingly, KYNA1 displayed the 
same effect as in in vivo experiments (similar to KYNA and MK-801), thus KYNA1 itself does affect 
opioid receptor G-protein activity. However, in case of KOP receptor in the cortex, the effect was 
opposite compared to in vivo experiments. Additionally, in some cases the in vitro results showed 
significant alterations where the in vivo setup did not. These differences between in vivo and in vitro 
results might be due to rapid peripheral metabolism of the compounds and the presence of the BBB.  
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The most striking result was the increase of KOP G-protein activity, which was only observed in the 
cortex following in vivo KYNA1 treatment. The increased KOP receptor activity induced by KYNA1 
treatment might be due to a compensatory mechanism of the KOP receptor, representing its 
neuroprotective effect against reduced cortex blood flow. Furthermore, during this mechanism KYNA1 
might be converted to KYNA in the cortex, exerting its vasoconstrictor effect at high dosage.  KYNA 
treatment did not affect KOP receptor activity in the cortex most probably because of its poor BBB 
penetration. 
 
 
 
 
Conclusion 
The present study for the first time provides evidence for an indirect, NMDA receptor-mediated 
mechanism regarding the effects of KYNA/KYNA1 on opioid receptor function at the receptor-G-
protein level. Thus KYNA and KYNA1 might be possible drug candidates for controlling the activity 
of the opioid system via the NMDA receptor, for instance, during opioid withdrawing in addiction 
therapy or pain management. 
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